Envista Q3 2026: Five-Quarter EPS Beat Streak and a Guidance Raise

Envista's Q3 2026 earnings report extended a streak that is becoming hard to ignore. The dental products company posted adjusted diluted EPS of $0.40, beating the $0.356 analyst consensus by 12.36%, marking the fifth consecutive quarter it has topped Wall Street's earnings estimate. Revenue of $691.5 million also cleared expectations, exceeding the $688.73 million estimate by roughly 0.4% and growing 3.2% year over year.

The profitability story was driven by margin expansion attributed to the Envista Business System, the company's internal operating framework. Adjusted operating margin widened to 13.7% from 12.8% a year ago, and adjusted EBITDA margin improved 80 basis points to 15.3%. Gross profit grew faster than revenue, up 6.8% year over year, signaling that cost execution is delivering genuine earnings leverage.

On the segment level, Equipment and Consumables led with core sales growth of 4.1% and saw its adjusted operating margin rise to 22.4% from 20.1% a year ago. Specialty Products and Technologies, which houses brands including Nobel Biocare, Ormco, and Spark, grew core sales 2.0% but saw its adjusted operating margin edge down slightly to 15.0% from 15.5%. Envista also opened a new European Design Center for Spark during the quarter, signaling continued investment in its clear aligner platform.

Management raised full-year 2026 adjusted diluted EPS guidance to $1.54 to $1.58, up from a prior range of $1.50 to $1.55, and tightened its core sales growth outlook to 3.75% to 4.25%. CEO Paul Keel cited the company's strong momentum and year-to-date progress as the basis for raising guidance once again. Full-year adjusted EBITDA growth guidance was also lifted to 12.5% to 14%, from a prior range of 11% to 14%, while free cash flow conversion guidance remains approximately 100%.

One item worth separating from the operating results is GAAP net income, which swung to $508.3 million from a prior-year loss of $30.3 million. That figure was heavily influenced by a non-cash $428.1 million foreign currency translation gain tied to legal entity simplification efforts rather than the underlying dental business. Investors focused on operational performance should anchor to the adjusted figures. On the capital allocation front, Envista repurchased approximately 386 thousand shares for roughly $10 million in the quarter, with about $273 million of remaining repurchase capacity at quarter end.